Limits...
Chinese herbal medicine formula Gu-Ben-Fang-Xiao-Tang attenuates airway inflammation by modulating Th17/Treg balance in an ovalbumin-induced murine asthma model

View Article: PubMed Central - PubMed

ABSTRACT

Gu-Ben-Fang-Xiao-Tang (GBFXT) is a traditional Chinese medicine formula consisting of 11 medicinal plants, which has been used in the treatment of asthma. The present study aimed to determine the protective effects and the underlying mechanisms of GBFXT on ovalbumin (OVA)-induced allergic inflammation in a mouse model of allergic asthma. A total of 50 mice were randomly assigned to the following five experimental groups: Normal, model, montelukast (2.6 mg/kg), 12 g/kg GBFXT and 36 g/kg GBFXT groups. Airway responsiveness was measured using the forced oscillation technique, while differential cell count in the bronchoalveolar lavage fluid (BALF) was measured by Wright-Giemsa staining. Histological assessment was performed by hematoxylin and eosin staining, while BALF levels of Th17/Treg cytokines were measured by enzyme-linked immunosorbent assay, and the proportions of Th17 and Treg cells were evaluated by flow cytometry. The results showed that GBFXT suppressed airway hyperresponsiveness during methacholine-induced constriction, reduced the percentage of leukocytes and eosinophils, and resulted in decreased absolute neutrophil infiltration in lung tissue. In addition, GBFXT treatment significantly decreased the IL-17A cytokine level and increased the IL-10 cytokine level in the BALF. Furthermore, GBFXT significantly suppressed Th17 cells and increased Treg cells in asthmatic mice. In conclusion, the current results demonstrated that GBFXT may effectively inhibit the progression of airway inflammation in allergic asthma, partially by modulating the Th17/Treg cell balance.

No MeSH data available.


Related in: MedlinePlus

Sensitization, challenge and treatment schedules, as performed in the present study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998120&req=5

f1-etm-0-0-3507: Sensitization, challenge and treatment schedules, as performed in the present study.

Mentions: A mouse asthmatic model was established as described previously (12). The sensitization, challenge and treatment schedules are shown in Fig. 1. In brief, mice (with the exception of those in the normal control group) were sensitized by intraperitoneal injection of 10 µg OVA and 1 mg aluminum hydroxide. The mice were sensitized twice, on days 0 and 7. One week after the second sensitization, mice (except those in the normal control group) were anesthetized with 2% isoflurane (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) and intranasally challenged with 100 µg OVA in 0.05 ml PBS once per day between days 14 and 21. Subsequently, mice were rechallenged with 2.5% OVA-PBS between days 22 and 28. In the GBFXT treatment groups (n=10/group), 12 or 36 g/kg GBFXT was administered orally once daily on days 22–28. Mice in the normal control group (n=10) were sensitized with PBS and were treated with PBS on days 22–28, whereas mice in the model control and in the positive control (termed montelukast group) groups (n=10/group) were treated orally with PBS and montelukast (2.6 mg/kg; Sigma-Aldrich), respectively, once daily on days 22–28. Animals were sacrificed by overdose with pentobarbital sodium (50 mg/kg) 48 h after the last challenge (on day 30) in order to characterize the effects of GBFXT.


Chinese herbal medicine formula Gu-Ben-Fang-Xiao-Tang attenuates airway inflammation by modulating Th17/Treg balance in an ovalbumin-induced murine asthma model
Sensitization, challenge and treatment schedules, as performed in the present study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998120&req=5

f1-etm-0-0-3507: Sensitization, challenge and treatment schedules, as performed in the present study.
Mentions: A mouse asthmatic model was established as described previously (12). The sensitization, challenge and treatment schedules are shown in Fig. 1. In brief, mice (with the exception of those in the normal control group) were sensitized by intraperitoneal injection of 10 µg OVA and 1 mg aluminum hydroxide. The mice were sensitized twice, on days 0 and 7. One week after the second sensitization, mice (except those in the normal control group) were anesthetized with 2% isoflurane (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) and intranasally challenged with 100 µg OVA in 0.05 ml PBS once per day between days 14 and 21. Subsequently, mice were rechallenged with 2.5% OVA-PBS between days 22 and 28. In the GBFXT treatment groups (n=10/group), 12 or 36 g/kg GBFXT was administered orally once daily on days 22–28. Mice in the normal control group (n=10) were sensitized with PBS and were treated with PBS on days 22–28, whereas mice in the model control and in the positive control (termed montelukast group) groups (n=10/group) were treated orally with PBS and montelukast (2.6 mg/kg; Sigma-Aldrich), respectively, once daily on days 22–28. Animals were sacrificed by overdose with pentobarbital sodium (50 mg/kg) 48 h after the last challenge (on day 30) in order to characterize the effects of GBFXT.

View Article: PubMed Central - PubMed

ABSTRACT

Gu-Ben-Fang-Xiao-Tang (GBFXT) is a traditional Chinese medicine formula consisting of 11 medicinal plants, which has been used in the treatment of asthma. The present study aimed to determine the protective effects and the underlying mechanisms of GBFXT on ovalbumin (OVA)-induced allergic inflammation in a mouse model of allergic asthma. A total of 50 mice were randomly assigned to the following five experimental groups: Normal, model, montelukast (2.6 mg/kg), 12 g/kg GBFXT and 36 g/kg GBFXT groups. Airway responsiveness was measured using the forced oscillation technique, while differential cell count in the bronchoalveolar lavage fluid (BALF) was measured by Wright-Giemsa staining. Histological assessment was performed by hematoxylin and eosin staining, while BALF levels of Th17/Treg cytokines were measured by enzyme-linked immunosorbent assay, and the proportions of Th17 and Treg cells were evaluated by flow cytometry. The results showed that GBFXT suppressed airway hyperresponsiveness during methacholine-induced constriction, reduced the percentage of leukocytes and eosinophils, and resulted in decreased absolute neutrophil infiltration in lung tissue. In addition, GBFXT treatment significantly decreased the IL-17A cytokine level and increased the IL-10 cytokine level in the BALF. Furthermore, GBFXT significantly suppressed Th17 cells and increased Treg cells in asthmatic mice. In conclusion, the current results demonstrated that GBFXT may effectively inhibit the progression of airway inflammation in allergic asthma, partially by modulating the Th17/Treg cell balance.

No MeSH data available.


Related in: MedlinePlus